Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer  by Kugel, Sita et al.
ReportIdentification of and Molecular Basis for SIRT6 Loss-
of-Function Point Mutations in CancerGraphical AbstractHighlightsd Eight loss-of-function SIRT6 mutations were identified in
human cancers
d SIRT6 mutants alter either SIRT6 stability, localization, or
enzymatic activity
d SIRT6 mutants fail to repress glycolysis and cellular
transformation
d Deacetylase, not demyristoylase, activity is critical for SIRT6
tumor-suppressor functionKugel et al., 2015, Cell Reports 13, 479–488
October 20, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.09.022Authors
Sita Kugel, Jessica L. Feldman,
Mark A. Klein, ..., GadGetz, JohnM.Denu,
Raul Mostoslavsky
Correspondence
jmdenu@wisc.edu (J.M.D.),
rmostoslavsky@mgh.harvard.edu (R.M.)
In Brief
Kugel et al. identified eight naturally
occurring tumor-associated point
mutations in SIRT6 that alter stability,
localization, or enzymatic activity. Based
on biochemical, biological, and structural
analyses, these mutations render SIRT6
unable to repress transformation. These
mutations demonstrate that SIRT6
deacetylase activity, not demyristoylase
activity, is critical for SIRT6 tumor-
suppressor functions.
Cell Reports
ReportIdentification of and Molecular Basis for SIRT6
Loss-of-Function Point Mutations in Cancer
Sita Kugel,1,7 Jessica L. Feldman,4,7 Mark A. Klein,4 Dafne M. Silberman,6 Carlos Sebastia´n,1 Craig Mermel,1,3
Stephanie Dobersch,5 Abbe R. Clark,1 Gad Getz,1,3 John M. Denu,4,* and Raul Mostoslavsky1,2,3,*
1The Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
2The Center for Regenerative Medicine, The Massachusetts General Hospital, Boston, MA 02114, USA
3The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
4The Department of Biomolecular Chemistry and the Wisconsin Institute for Discovery, University of Wisconsin, Madison, WI 53715, USA
5Max-Planck-Institute for Heart and Lung Research, Bad Nauheim 61231, Germany
6Center for Pharmacological and Botanical Studies (CEFYBO)-CONICET, Facultad de Medicina, UBA, Buenos Aires 1121, Argentina
7Co-first author
*Correspondence: jmdenu@wisc.edu (J.M.D.), rmostoslavsky@mgh.harvard.edu (R.M.)
http://dx.doi.org/10.1016/j.celrep.2015.09.022
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Chromatin factors have emerged as the most
frequently dysregulated family of proteins in cancer.
We have previously identified the histone deacety-
lase SIRT6 as a key tumor suppressor, yet whether
point mutations are selected for in cancer remains
unclear. In this manuscript, we characterized natu-
rally occurring patient-derived SIRT6 mutations.
Strikingly, all the mutations significantly affected
either stability or catalytic activity of SIRT6, indi-
cating that these mutations were selected for in
these tumors. Further, the mutant proteins failed to
rescue sirt6 knockout (SIRT6 KO) cells, as measured
by the levels of histone acetylation at glycolytic
genes and their inability to rescue the tumorigenic
potential of these cells. Notably, the main activity
affected in the mutants was histone deacetylation
rather than demyristoylation, pointing to the former
as the main tumor-suppressive function for SIRT6.
Our results identified cancer-associated point muta-
tions in SIRT6, cementing its function as a tumor sup-
pressor in human cancer.
INTRODUCTION
The (NAD)+-dependent histone deacetylase, SIRT6, is a
mammalian sirtuin with broad functions including glucose ho-
meostasis, maintenance of genome stability, and suppression
of cellular transformation (Mostoslavsky et al., 2006; Sebastia´n
et al., 2012; Zhong et al., 2010). In this context, SIRT6 co-re-
presses both HIF1a and MYC by deacetylating histone 3 (H3)
lysine 9 (K9) and lysine 56 (K56) at the promoters of several
glycolytic and ribosomal protein genes. Consequently, SIRT6-
deficient cells display increased glycolysis even under normoxic
conditions, a phenomenon termed aerobic glycolysis by Otto
Warburg, who first described this phenotype in cancer cellsC(Warburg, 1956). Indeed, SIRT6 inhibits cancer growth in a
manner that depended on glycolytic metabolism (Sebastia´n
et al., 2012). Importantly, we found SIRT6 commonly downregu-
lated or deleted in human cancer, where lower SIRT6 expression
is associated with poor prognosis. Thus, SIRT6 acts as a key
tumor suppressor and critical node between cellular transforma-
tion and metabolism (Sebastia´n et al., 2012).
SIRT6-dependent phenotypes have been attributed to its
intrinsic histone deacetylase activity, which seems negligible in
biochemical assays, but can be enhanced by binding to nucleo-
somes and/or long-chain fatty acids (Feldman et al., 2013; Gil
et al., 2013; Kawahara et al., 2009;Michishita et al., 2008; Sebas-
tia´n et al., 2012; Zhong et al., 2010). Recent studies have shown
that SIRT6 can also function as a protein demyristoylase (Feld-
man et al., 2013; Jiang et al., 2013), introducing the possibility
that SIRT6 may suppress tumorigenesis through the deacylation
of long-chain fatty acyl groups rather than histone deacetylation.
The lack of known SIRT6 point mutations selected for in human
cancer has hindered progress in the molecular understanding of
the tumor-suppressive roles of SIRT6.
In this manuscript, we identify and characterize eight naturally
occurring tumor-associated point mutations in SIRT6 that alter
stability, localization, and/or enzymatic activity and characterize
their ability to repress HIF1a and MYC transcriptional activity,
glycolytic metabolism, and cellular transformation.
RESULTS
SIRT6 Is Mutated in a Variety of Human Cancers
In order to determine whether SIRT6 could be inactivated in hu-
man tumors through point mutations, we analyzed somatic
mutations obtained via exome sequencing of patient-derived tu-
mor samples from 12 tumor types in the TCGA and found eight
somatic mutations in SIRT6. These mutations were found in a
variety of tumor types such as non-small-cell lung cancer, renal
clear cell carcinoma, cervical carcinoma, and melanoma (Fig-
ure 1A). Although SIRT6 did not meet statistical significance as
a result of the low frequency of mutations (Lawrence et al.,
2014; http://www.tumorportal.org), all of the mutations wereell Reports 13, 479–488, October 20, 2015 ª2015 The Authors 479
Figure 1. Identification of Patient-Derived SIRT6 Loss-of-Function Mutations in Cancer
(A) Table of patient-derived SIRT6 point mutations, the disease, type of mutation, and amino acid change.
(B) Alignment of metazoan SIRT6 homologs. Red boxes highlight the position of the mutations in the N terminus (red), catalytic core (yellow), or C terminus (blue).
(C) Western blot of chromatin fraction in SIRT6 KO MEFs with doxycycline-inducible overexpression of wild-type (WT) SIRT6 and SIRT6 mutants.
(D) Sub-cellular localization of WT and mutant SIRT6 proteins. Fluorescent images of fixed 293T cells transiently transfected with the indicated EGFP-tagged
SIRT6 deletion and point mutants are shown. Nuclei are co-stained with DAPI (403).
(E) Thermal denaturation assays were performed to determine the melting temperature (Tm) of WT (circle), D25N (square), D63Y (triangle), and D116N (upside-
down triangle) SIRT6. A graph with representative experiments is shown. At least three trials were performed for each SIRT6 variant.nonsynonymous; seven of them were missense mutations,
and one mutation was a nonsense mutation, suggesting that
they may have functional relevance. The mutations occurred
throughout the protein and involved residues that are highly
conserved from flies to humans (Figure 1B). Mutations occurring480 Cell Reports 13, 479–488, October 20, 2015 ª2015 The Authorsin the N terminus include an aspartic acid at position 25 mutated
to asparagine (D25N) and a glutamic acid at position 36 mutated
to valine (E36V). Catalytic domain mutations include an aspartic
acid at position 63 mutated to tyrosine (D63Y), an alanine at po-
sition 89 mutated to serine (A89S), an aspartic acid at position
116 mutated to asparagine (D116N), a threonine at position 263
mutated to a proline (T263P), and finally a glutamic acid at posi-
tion 260 replaced with a stop codon (E260Term), leading to pre-
mature truncation of the protein and loss of the C terminus and
nuclear localization signal. Only one mutation involved the C ter-
minus, where a proline at position 274 was mutated to a lysine
(P274L) (Figures 1A and 1B).
SIRT6PointMutations that Alter Localization or Stability
Each of these SIRT6 mutations were cloned and expressed in
sirt6 knockout (SIRT6 KO) mouse embryonic fibroblasts
(MEFs). We also included, as a control, a variant found in the hu-
man population, N46S. Three of the mutants (D25N, D116N, and
E260Term) demonstrated reduced chromatin-bound and whole-
cell lysate protein levels, despite equivalent mRNA expression,
suggesting mislocalization or poor protein stability (Figures 1C,
S1A, and S1B). We noted that the appearance of reduced
expression with the D25N mutant may have been an artifact of
reduced antibody affinity because the antibody epitope includes
D25. Therefore, we used aGFP antibody to detect a GFP-tagged
version of wild-type (WT) SIRT6 and each of the SIRT6 mutants
to confirm that SIRT6 D25N expression and localization to
chromatin was equivalent to WT (Figure S1C), whereas the
D116N and E260Term mutants displayed reduced levels in
chromatin, as observed with the non-GFP-tagged constructs
(Figure 1C). We also noted that each of the mutant alleles local-
ized to the nucleus, except for the E260Term mutant, consistent
with the lack of a nuclear localization signal (Figure 1D). Interest-
ingly, the levels of the D116N mutant were consistently reduced
both in the chromatin fraction when expressed in mammalian
cells and when recombinantly overexpressed in E. coli, suggest-
ing defective protein stability. To test this hypothesis, we
determined the melting temperature of D116N, D25N, D63Y,
and WT SIRT6. Whereas D25N (43.74C ± 0.04C) and D63Y
(45.8C ± 0.1C) exhibited melting temperatures very similar
to WT (46.08C ± 0.05C), the melting temperature of D116N
was 13C lower (33.4C ± 0.6C; Figure 1E). At physiologic
temperatures, this protein is expected to be largely unfolded
and subject to degradation.
In Silico Analysis Predicts Functionally Significant
Structural Changes Induced by Cancer-Associated
SIRT6 Mutations
To gain insight into the functional significance of these mutated
residues, we analyzed the previously solved co-crystal structure
of SIRT6 bound to ADP-ribose and an H3K9 myristoylated pep-
tide (PDB: 3ZG6; Jiang et al., 2013; Figure 2A). Aspartic acid 25 is
located in the N-terminal domain (NTD) and hydrogen bonds to
the backbone amide nitrogen and carbonyl oxygen of H255 as
well as to the ε-amino group of K33 (Figure 2B). The NTD is
required for catalytic activity and chromatin association (Tennen
et al., 2010); therefore, amutation to asparagine will likely disrupt
the orientation and interactions between the loop and the Ross-
mann-fold domain. Aspartic acid 63 is located in the NAD+-bind-
ing pocket, 3 A˚ from the adenosine moiety of NAD+, and forms
hydrogen-bonding interactions with amino acids in the active
site (Figure 2C). Therefore, a mutation to tyrosine is predicted
to have a highly detrimental effect on the ability of SIRT6 toCbind NAD+ and catalyze deacetylation. Alanine 89 and aspartic
acid 116 are located on loops in the back of the active site (Fig-
ures 2D and 2E). Alanine 89 forms a backbone hydrogen bond
interaction with T85, and mutation to serine might affect the
orientation of this loop. The invariant aspartic acid residue
(D116) forms a hydrogen bond to the carboxamide amino group
of nicotinamide, and mutation to glutamine will disrupt this
conserved interaction. Glutamic acid 36 and threonine 263 are
located in the Rossmann-fold domain and form hydrogen bonds
with R39 andD259, respectively (Figures 2F and 2G). Mutation of
E36 to valine will abolish this hydrogen bond, which could desta-
bilize other interactions in the helix. A proline mutation at T263
will disrupt the structure of the helix in the Rossmann-fold. Pro-
line 274 is located in the proline-rich C-terminal domain (CTD)
loop, and a mutation to threonine may affect the orientation of
the loop (Figure 2H). Taken together, all of the identified muta-
tions are likely to affect catalytic activity directly or through struc-
tural rearrangements.
Deacetylase Activity of SIRT6 Mutants
We next performed a highly sensitive, quantitative, in vitro
deacetylase assay on purified recombinant SIRT6 mutants and
compared the results obtained with WT enzyme. First, WT or
SIRT6 mutants were reacted with 50 mM H3K9Ac peptide
and 0.5 mM NAD+. Reaction substrates and products were
separated by HPLC and quantified. Strikingly, all mutants
displayed decreased deacetylase activity relative to WT SIRT6
(3.9 ± 0.3 3 104 mmol min1 mg SIRT61). D25N, E36V, A89S,
T263P, and P274L all exhibited approximately 50% of WT
SIRT6 activity, whereas D116N and D63Y yielded nearly negli-
gible deacetylase activity at 2% of WT SIRT6 levels (Figure 2I).
Importantly, the non-cancer-associated N46S variant displayed
deacetylase activity similar toWT. The decreased catalytic activ-
ity of D116NSIRT6 is due in part to decreased protein stability, as
evidenced by its 13C lower melting temperature. Additionally,
the invariant D116 residue is located in the nicotinamide-binding
pocket of SIRT6 and plays a direct role in NAD+ binding (Fig-
ure 2E). The corresponding aspartic acid residue in the crystal
structure of bacterial Sir2Tm forms a hydrogen bond with the
carboxamide amino group of the nicotinamide moiety. Mutation
of the aspartic acid residue to an asparagine decreased the
catalytic efficiency of Sir2Tm by two orders of magnitude
(Avalos et al., 2005). Therefore, as predicted, a mutation of
D116 to asparagine led to a similar reduction in SIRT6 activity.
We recently demonstrated that SIRT6 can be directly acti-
vated by long-chain fatty acids in vitro (Feldman et al., 2013).
To assess the ability of fatty acids to activate these SIRT6 mu-
tants, we analyzed the in vitro deacetylase activity in the pres-
ence of myristic acid. WT and SIRT6 mutants were reacted
with 50 mM H3K9Ac peptide and 0.5 mM NAD+ in the presence
of 300 mM myristic acid. The fold change in activity of each
mutant in the presence of myristic acid was compared to WT.
D25N (11 ± 0.5) and E36V (11 ± 2) were activated by myristic
acid to the same level as WT SIRT6 (10 ± 1), whereas P274L
(7 ± 1) and T263P (6 ± 1) were activated to a slightly lesser extent
than WT (Figure 2J). Interestingly, the activity of A89S SIRT6
decreased 2-fold in the presence of myristic acid, which resulted
in a 20-fold decrease in activation relative to WT.ell Reports 13, 479–488, October 20, 2015 ª2015 The Authors 481
Figure 2. Structural and Enzymatic Analysis of WT SIRT6 and SIRT6 Point Mutations
(A) Locations of mutated residues mapped on the crystal structure of SIRT6 (PDB: 3GZ6).
(B–H) Zoomed-in view of the mutated residues highlighted in red. Also displayed are residues in close proximity to the mutated residues and hydrogen bonding
interactions.
(I) SIRT6 deacetylase activity measured in vitro. Recombinant WT and SIRT6 mutants (2 mM) were incubated with 50 mM H3K9Ac peptide and 0.5 mM NAD+.
(J) Fold change in SIRT6-dependent deacetylation in the presence of 300 mM myristic acid.
(legend continued on next page)
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To determine whether cancer-associated mutations in SIRT6
affect the previously reported demyristoylase activity (Jiang
et al., 2013), WT and SIRT6 mutants were reacted with 50 mM
H3K9Myr peptide in the presence of 0.5 mMNAD+ and analyzed
as described above. As predicted, the N46S variant, which was
used as a control in the assay, displayed demyristoylase activity
equal to WT. Surprisingly, the D25N, E36V, A89S, and P274L
mutations displayed similar ability to remove myristoyl groups
compared with WT SIRT6 (R75%). The demyristoylase activity
of T263P activity was greater than 70% of WT, whereas D63Y
and D116N were the only two mutants that exhibited less than
5% demyristoylase activity (Figure 2K), which is consistent
with loss of general catalytic function. Importantly, these data
suggest that cancer-associated point mutationsmay specifically
inactivate SIRT6 deacetylase activity without affecting its ability
to remove larger fatty acyl groups. Most dramatic is the A89S
mutant, which displays similar demyristoylation activity to that
of WT but cannot be activated toward acetylated histone sub-
strates (compare Figures 2J and 2K).
To examine the effect of SIRT6 mutations on histone acetyla-
tion in vivo, we analyzed total H3K9 and H3K56 acetylation levels
in bulk chromatin of MEFs following short-term expression of
either WT or mutant SIRT6 using a dox-inducible system. In
this context, the D25N, D63Y, D116N, and E260Term mutants
failed to reduce levels of H3K56 and K9 acetylation when
compared to WT SIRT6 (Figure 2L). This is consistent with the
reduced deacetylase activity of the D25N and D63Y mutations
and the reduced binding of the D116N and E260Term mutants
to chromatin. The D25Nmutant behaves similarly to a previously
described, catalytically inactive mutation where the highly
conserved histidine 133, within the core sirtuin domain of
SIRT6, is mutated to tyrosine (H133Y; Mostoslavsky et al.,
2006). The SIRT6 mutants E36V, A89S, T263P, and P274L
were able to reduce the levels of acetylated H3K56 and
H3K9 in bulk chromatin when overexpressed, despite having
decreased in vitro catalytic activity relative to WT (compare Fig-
ures 2I and 2L), suggesting that overexpression can overcome
their reduced enzymatic activity. However, these changes in
bulk chromatin may not specifically reflect the effect of these
SIRT6 mutants to deacetylate histones in the promoter regions
of specific SIRT6-regulated genes.
The D63Y mutant displays limited deacetylase and demyris-
toylase activity and led to large increases in acetylation in vivo.
As described earlier, D63 is located in the NAD+-binding pocket
and is 3 A˚ from the adenosine moiety of NAD+ (Figure 2C).
To test the hypothesis that D63Y decreases the affinity of
SIRT6 for NAD+, we performed steady-state kinetic analysis
with increasing NAD+ at saturating levels of H3K9Myr peptide.
The H3K9Myr peptide was used in the assay due to the prohibi-
tively high concentration of H3K9Ac peptide required for satura-(K) SIRT6 demyristoylase activity measured in vitro. WT and SIRT6 mutants (0.
nR 3; ±SD; **p% 0.01; ***p% 0.001; ns, p > 0.05).
(L) Western blot of chromatin fraction in SIRT6 KOMEFs with doxycycline-inducib
blots from Figure 1C are represented here for direct comparison.
(M) Steady-state rates of demyristoylation were measured by varying NAD+ (25–1
Calculated values determined from non-linear regression fits to Michaelis-Mente
values previously published (Feldman et al., 2015).
Ction (estimated at nearly 4.5 mM; Feldman et al., 2013). The data
were subjected to Michaelis-Menten analysis, and the kinetic
constants were compared to WT SIRT6, as well as to A89S
and T263P, which were expected to show no defects in NAD+
affinity (Figures 2M and S1E). The kcat/Km value is the lowest
for D63Y (7.2 ± 0.9 s1 M1) and is 125 times less efficient than
WT SIRT6 (9.0 ± 0.63 102 s1M1). Whereas the small decrease
in the catalytic efficiency of A89S (6.3 ± 0.5 3 102 s1 M1) and
T263P (2.5 ± 0.3 3 102 s1 M1) is caused by a decrease in
the kcat, the decrease in D63Y is due to both a decrease in kcat
and an increase in the Km for NAD
+. The Km for NAD
+ increased
approximately seven times (90 ± 10 mM versus 13 ± 1 mM),
and the kcat decreased 19 times relative to WT SIRT6 (6.3 ±
0.23104 s1M1 versus 1.20±0.023102 s1M1). Together,
the results indicate a mutation of D63 to tyrosine disrupts both
the affinity of SIRT6 for NAD+ and catalysis, leading to dramatic
loss of SIRT6-dependent deacetylation and the subsequent
robust increase in acetylation observed in vivo.
SIRT6 Mutants Fail to Repress Glycolytic Genes
We next determined the ability of the mutants to repress HIF1a
and MYC transcriptional activity. As shown in Figures 3A and
3B, both HIF1a and MYC luciferase reporters were repressed
by WT SIRT6; however, the mutants were unable to repress
either HIF1a or MYC luciferase activity. We next expressed
each of these mutants as well as WT SIRT6 in SIRT6 KO
MEFs. Consistent with their inability to repress HIF1a and MYC
transcriptional activity, the SIRT6 mutants were unable to
decrease glucose uptake by SIRT6 KO MEFs (Figure 3C). Simi-
larly, these mutants were unable to repress the glycolytic genes
pfkm, pdk1, and ldhb (Figure 3D) and the ribosomal genes rpl3,
rpl23, and rps15a (Figure S2B). Interestingly, E36V, T263P, and
P274L were still able to partially inhibit glucose uptake. Thus,
we tested additional genes that may explain why these SIRT6
mutants may be able to repress glucose uptake and found
that, unlike other glycolysis-related genes, these mutants retain
the ability to silence the glucose transporter 1 (glut1), a SIRT6
target gene that is directly responsible for controlling glucose
uptake (Figure S2A). Taken together, these results suggest that
these cancer-associated SIRT6 mutations are unable to repress
MYC- and HIF1a-dependent transcription.
To further explore the mechanism by which SIRT6 regulates
glycolytic gene expression, we performed chromatin immuno-
precipitation (ChIP) for H3K9Ac, H3K56Ac, and SIRT6 in cells ex-
pressing SIRT6 WT and mutant alleles H133Y, D63Y, A89S, and
D116N. We found that WT SIRT6 binds to pdk1, glut1, ldha, and
ldhb and is able to deacetylate H3K56, as previously reported
(Figures 3E and 3F; Zhong et al., 2010), thus leading to the
reduced gene expression we observed in Figure 3D. The
SIRT6 mutants D63Y and A89S were able to bind to the5 mM) were incubated with 50 mM H3K9Myr peptide and 0.5 mM NAD+ (I–K;
le overexpression of WT SIRT6 and SIRT6mutants. SIRT6 and H3 total western
,200 mM) in the presence of 0.5 mM D63Y SIRT6 and 50 mM H3K9Myr peptide.
n are shown below for WT, D63Y, A89S, and T263P (nR 3; ±SD). *WT SIRT6
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Figure 3. SIRT6 Cancer-Associated Point Mutations Fail to Repress HIF and MYC
(A and B) Luciferase reporter gene assay for MYC (A) and HIF1a (B) in 293T cells transiently expressing the indicated SIRT6 constructs. Data are shown asmean ±
SEM between triplicates and are representative of four independent experiments.
(C) NBDG-glucose uptake in SIRT6 KO MEFs. Data are shown as mean ± SEM between duplicates and are representative of two independent experiments.
(D) Quantitative real-time PCR showing the expression of indicated genes. Data are shown as mean ± SEM between duplicates in six independent experiments.
(E and F) Chromatin immunoprecipitation for SIRT6 (E) and H3K56Ac (F) in SIRT6 KO MEFs expressing the indicated SIRT6 constructs followed by qPCR
amplification of the indicated glycolytic genes. Data are shown as mean ± SEM between duplicates.
*p% 0.05; **p% 0.01; ***p% 0.001.glycolytic genes, whereas D116Nwas unable to bind, most likely
due to its reduced protein stability (Figure 3E). Similar to our pre-
vious in vitro and cellular characterization data, H133Y, D63Y,
A89S, and D116N were unable to deacetylate H3K56 to the484 Cell Reports 13, 479–488, October 20, 2015 ª2015 The Authorssame degree as WT SIRT6 (Figure 3F). Interestingly, we also
observed that expression of WT SIRT6 had a less-dramatic
impact on H3K9Ac levels both in bulk chromatin (Figure 2L)
and over the promoters of specific SIRT6 target genes
Figure 4. SIRT6 Cancer-Associated Point Mutations Fail to Repress Anchorage-Independent Growth
(A) Quantification of colonies grown in soft agar of SIRT6 KO MEFs expressing each mutant. Data are shown as mean ± SEM between triplicates in four in-
dependent experiments.
(B) Representative pictomicrographs of colonies.
(C) Gross images of subcutaneous tumors grown in SCID mice of SIRT6 KO cells re-expressing the indicated SIRT6 constructs (n = 5).
(D) Quantification of tumor weight from (C).
*p% 0.05; **p% 0.01; ***p% 0.001.(Figure S2C), suggesting that removal of H3K56Acmarksmay be
more critical for SIRT6-mediated gene repression in this system.
SIRT6 Mutants Fail to Suppress Anchorage-
Independent Growth and Tumor Formation
To assess the ability of these SIRT6 mutants to repress transfor-
mation, we first performed soft agar colony-formation assays on
our SIRT6 KO MEFs engineered to express either empty vector,
WT SIRT6, or each of our cancer-associated mutations. Indeed,
we found that all of the tumor-associated mutations were unable
to suppress colony formation in soft agar to the same degree as
WT SIRT6 (Figures 4A and 4B). The only exceptions were T263P
and P274L, consistent with their ability to suppress glucose
uptake, indicating that overexpression of either mutant may be
sufficient to overcome its reduced enzymatic activity. Thus,
the histone deacetylase activity of SIRT6 seems critical to sup-
press cellular transformation. To test these mutants in a more
stringent environment, we implanted D25N, A89S, D116N,
E260Term, the variant N46S, and WT SIRT6 subcutaneously
into the flanks of SCID mice and monitored tumor growth over
2 months. Strikingly, the cells expressing the different mutants
readily formed tumors, whereas cells re-expressing WT SIRT6
and the variant N46S formed negligible tumors (Figures 4CCand 4D). These results indicate that these specific mutations
eliminate the capacity of SIRT6 to protect against tumor forma-
tion in vivo.
DISCUSSION
Using data mining from The Cancer Genome Atlas (TCGA), we
identified eight point mutations in SIRT6, which spontaneously
arose in a variety of human cancers. Based on biochemical, bio-
logical, and structural analysis, we find that these mutations
render the protein unable to fully repress HIF1a and MYC tran-
scriptional activity, resulting in a glycolytic switch and cellular
transformation. Importantly, several of thesemutations decrease
SIRT6 deacetylase activity while maintaining the ability to re-
move myristoyl groups, demonstrating that SIRT6 deacetylase
activity, as opposed to the demyristoylase activity, is critical
for its major tumor-suppressor functions (Table S1). Thus,
although rare, point mutations in SIRT6 are selected for in human
cancers, further highlighting SIRT6 as a tumor suppressor and its
molecular function as a histone deacetylase repressing both pro-
growth and glycolytic phenotypes.
From a genetic perspective, tumor suppressors, in contrast to
oncogenes, are frequently deleted, silenced, and, less often,ell Reports 13, 479–488, October 20, 2015 ª2015 The Authors 485
mutated (Vogelstein et al., 2013). Although in previous work, we
identified deletion and transcriptional silencing of SIRT6 as
mechanisms through which tumors eliminate or reduce SIRT6
activity, in this study, we aimed to identify whether specific point
mutations in SIRT6 could provide tumors with a selective growth
advantage. Also, such precise mutations might provide the op-
portunity to determine which catalytic activity of SIRT6 is the
main driver of tumor suppression, as sirtuins are now recognized
as general protein deacylases (Feldman et al., 2013). Strikingly,
each one of the cancer-associated mutations we identified
clearly reduced SIRT6 function, either by affecting SIRT6 protein
stability or catalytic activity.
The mutations were distributed broadly throughout the gene,
suggesting that, likely, no particular hot spots evolved that
selectively affect SIRT6 activity. When analyzed for protein sta-
bility, two specific mutations (D116N and E260Term) exhibited
less chromatin binding and protein levels, despite normal RNA
expression. E260Termwas the only mutation that lacked nuclear
staining, consistent with a deletion of the nuclear localization
signal in this mutant. D116N, in turn, appears to directly affect
stability of the protein, as confirmed by a strong decrease in
melting temperature compare to WT SIRT6. At physiologic
temperatures, this protein will mostly remain unfolded and be
subjected to degradation. All the other mutations affected
SIRT6 catalytic activity. D63Y significantly affects NAD+ binding,
whereas D25N, E36V, A89S, T263P, and P274L mutations are
not directly involved in binding the acetylated substrate or
NAD+ and likely decrease SIRT6 activity by imposing specific
structural defects that alter the deacetylase function.
The SIRT6 A89Smutant is especially intriguing given that it ex-
hibits deacetylase activity that is approximately 50%ofWT in the
absence of activation by myristic acid in our in vitro assays.
Whereas not dramatically inhibiting basal in vitro deacetylase ac-
tivity of SIRT6, the A89S mutation prevents SIRT6 from reaching
maximal activity level in the presence of free fatty acid. A89 is
located on a loop in the back of the active site and forms a back-
bone hydrogen-bonding interaction with T85 in the loop (Fig-
ure 2D). Thus, mutation of A89 to a serine likely alters the
orientation of the loop, disfavoring myristic acid binding. In this
context, the activity of the A89S mutant is comparable with the
D116N mutant. Therefore, we propose that both basal and
enhanced (i.e., with free fatty acid) activity of SIRT6 may be
important for its tumor-suppressive effects. The A89Smutant re-
duces the levels of H3K9Ac and H3K56Ac in bulk chromatin
similar to WT SIRT6. However, when looking at specific
SIRT6 target genes, the A89S mutant is defective in removing
H3K56Ac groups from specific SIRT6 target genes, such as
pdk1, glut1, ldha, and ldhb. Additionally, the A89S mutation dis-
plays a more-pronounced effect on tumor growth in vivo
compared to its ability to form colonies in soft agar. This may
reflect the inability of the A89S mutant to be activated by free
fatty acids or a functionally related small molecule that is present
in vivo, but not in vitro.
Interestingly, ChIP analysis revealed that SIRT6 deacetylated
H3K56Ac more efficiently than H3K9Ac at the promoters of
glycolytic genes. This is suggestive of a role for H3K56Ac in
gene silencing, consistent with our previous publication (Sebas-
tia´n et al., 2012). It is also important to note that we cannot486 Cell Reports 13, 479–488, October 20, 2015 ª2015 The Authorscompletely rule out that some of the phenotypes observed could
be due to the possibility that thesemutations affect the binding of
SIRT6 with other yet to be described partners, thus influencing
their regulation and function. Finally, whereas all cancer-associ-
ated mutations had decreased deacetylase activity, the N46S
variant found in the human population displayed WT level activ-
ity, providing additional evidence these mutations were specif-
ically selected for in these cancers.
Recent studies identified a de-fatty acylase activity for
SIRT6, by virtue of its capacity to modulate TNFa secretion
by removing a myristoyl group (Jiang et al., 2013). This recently
characterized activity has created mechanistic uncertainty as to
whether SIRT6 functions predominantly as a long-chain deacy-
lase or as a H3K9 and H3K56 deacetylase in order to regulate
cellular activity. Notably, all the cancer mutants exhibit clear
defective histone deacetylation activity, whereas their demyris-
toylase activity was similar to the WT enzyme, with the
exception of D63Y and D116N, which affect NAD+ binding.
Additionally, ADP-ribosylation activity has also been ascribed
to SIRT6. However, consistent with published reports (Du
et al., 2009; Feldman et al., 2012; Tanner et al., 2000), we
were unable to detect significant evidence of any ADP-ribosy-
lation activity by WT SIRT6 or any of the mutants we tested
(data not shown), suggesting that such activity for SIRT6 may
only be observed under specific circumstances (Mao et al.,
2011). These results indicate that histone deacetylation is
the main activity conferring tumor-suppressive functions to
SIRT6, likely through its ability to repress glycolytic and ribo-
somal protein gene expression, as we previously published
(Sebastia´n et al., 2012).
Taken together, our results provide convincing mechanistic
evidence for a tumor-suppressive role for this enzyme and in-
crease our understanding of the interplay between epigenetics,
metabolism, and cancer.EXPERIMENTAL PROCEDURES
Cell Lines
SIRT6 KO primary MEFs were generated from 13.5-day-old embryos as
described (Mostoslavsky et al., 2006). These cells were immortalized by using
the standard 3T3 protocol. Please see Supplemental Experimental Procedures
for culture conditions.
Computational Analysis to Identify SIRT6 Mutations
Somatic mutations in SIRT6 were obtained from Lawrence et al. (2014), which
are available at http://www.tumorportal.org. Details on discovery of somatic
mutations are found in Lawrence et al. (2014).
Expression and Purification of Recombinant Human SIRT6
His-tagged WT and mutant SIRT6 proteins were overexpressed in BL21(DE3)
E. coli strain, as previously described (Feldman et al., 2015). Cells were har-
vested by centrifugation and stored at 80C. SIRT6 WT and mutant proteins
were purified by nickel affinity resin chromatography as reported previously
(Pan et al., 2011). Protein concentrations were determined by the Bradford re-
agent assay.
Gel Electrophoresis and Western Blotting
Chromatin fractions and western blot analysis was performed as previously
described (Sebastia´n et al., 2012); details are listed in Supplemental Experi-
mental Procedures. Antibodies used were anti-SIRT6 (Abcam; ab62739),
anti-H3K9Ac (Millipore 07-352), anti-H3K56Ac (ab76307), anti-GFP (ab290), or
total-H3 (ab1791) as a loading control.
Immunofluorescence
293T cells were transfected using Trans-IT 293 (Mirus) with empty vector,
pEGFP-SIRT6, or the SIRT6 mutant constructs. Twenty-four hours after trans-
fection, cells were trypsinized and seeded onto 8-well chamber slides and
allowed to adhere overnight. Cells were then fixed using a 2% paraformalde-
hyde in a 1% PBS solution, permeabilized with 0.1% sodium citrate and 0.1%
Triton X-100, and nuclei were stained using DAPI. Images were taken using a
fluorescent microscope.
Statistics
For steady-state deacylation assays, real-time RT-PCR analysis, glucose up-
take, luciferase reporter assay, ChIP assay, anchorage-independent growth,
and tumor size, significance was analyzed using two-tailed Student’s t test.
A p value of less than 0.05 was considered statistically significant.
Thermal Denaturation Assays
Thermal denaturation assays were performed to determine the melting tem-
perature (Tm) of WT, D25N, D63Y, and D116N SIRT6. Purified proteins were
diluted to 10 mM (20 mM sodium phosphate [pH 7.5]) containing 3.753 Sypro
Orange (Invitrogen; delivered at 5,0003). Samples (35 ml) were aliquoted into
PCR strip tubes and placed in a Bio-Rad CFX96 Real-Time System C1000
thermal cycler. The temperature was increased at a rate of 0.5C/min over a
range of 10C–95C, and fluorescence was monitored with the FRET chan-
nels. At least three trials were performed for each SIRT6 variant. Themeasured
fluorescence was normalized so that the minimum fluorescence was set to 0
and the maximum fluorescence set to 1. The data were fitted to Equation 1
as previously utilized by Albaugh et al. (2011) to obtain the Tm,
I=

1
1+ eðTmTÞ=C

; (Equation 1)
where I is the normalized fluorescence value at temperature T and C is a slope
factor.
HPLC Deacylation Assay
Peptides corresponding to residues 4–17 of histone H3 (acetyl: AcQTARKac
STGGKAPR-WW-NH2 and myristoyl: Ac-QTARKmyrSTGGKAPRWW-NH2)
were synthesized as described previously (Feldman et al., 2013). Deacylation
reactions were analyzed by reversed phase high-performance liquid
chromatography on Kinetex C18 column (100 A˚; 100 3 4.6 mm; 2.6 mm; Phe-
nomenex) by monitoring the formation of the deacylated product at 214 nm
(Feldman et al., 2013) and also described in Supplemental Experimental
Procedures.
Steady-State Kinetic Analyses
Steady-state rates were measured by varying NAD+ (2–1,200 mM) in the pres-
ence of 0.5 mM WT, D63Y, A89S, or T263P SIRT6 and 50 mM NAD+ in 20 mM
sodium phosphate (pH 7.5) at 37C. Initial velocities were determined and data
were fitted to the Michaelis-Menten equation.
Glucose Uptake Assay
Cells were grown under normal conditions for 24 hr, and 100 mM 2-NBDG
(Invitrogen) was added to the media for 2 hr. Fluorescence was measured
by flow cytometry using a FACSCalibur Analyzer (BD).
Luciferase Reporter Assay
MYC and HIF1a transcriptional activity was determined in 293T cells using
pMYC-luc and mpGL3:HRE4 constructs, respectively, by luciferase reporter
assay as previously described (Sebastia´n et al., 2012; Zhong et al., 2010); de-
tails are listed in Supplemental Experimental Procedures.
Real-Time RT-PCR Analysis
Total RNA was extracted with the TriPure Isolation Reagent (Roche) as
described by the manufacturer. For cDNA synthesis, 1 mg of total RNA wasCreverse transcribed by using the QuantiTect Reverse Transcription Kit
(QIAGEN). Real-time PCR was performed as previously described (Sebastia´n
et al., 2012); details are listed in Supplemental Experimental Procedures. Data
were expressed as relative mRNA levels normalized to the b-actin expression
level in each sample. The primer sequences are listed in Table S2.
ChIP Assays
ChIP assays were performed as previously described (Sebastia´n et al., 2008),
with some modifications; details are listed in Supplemental Experimental Pro-
cedures. Antibodies used are 5 ml anti-SIRT6 (Abcam; ab62739), 5 ml anti-
H3K9Ac (Millipore 07-352), and 5 ml anti-H3K56Ac (ab76307). A control was
performed with unspecific IgGs (AbCam). Real-time RT-PCR was performed
with primers listed in Table S2.
Anchorage-Independent Growth
Five thousand cells were resuspended in 0.4% agar and plated in triplicates in
6-well plates containing a 0.8% base agar layer. Colonies were grown in the
presence of doxycycline for 3 months and counted. Media was changed every
3 days.
Xenografts
4 3 106 cells in 100 ml of 50% Matrigel were injected subcutaneously into
the flanks of SCID mice (n = 5; Taconic Farms) that were maintained on doxy-
cycline (200 mg/ml) in their drinking water. Mice were checked for the appear-
ance of tumors twice a week, and the tumors were harvested when they
reached 100 mm3 in size. These experiments were approved by the IACUC
Committee of MGH, protocol number 2007N000200.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.09.022.
AUTHOR CONTRIBUTIONS
S.K., J.L.F., M.A.K., S.D., and A.R.C. collected the data. S.K., J.L.F., and
M.A.K. analyzed the data. R.M., D.M.S., C.S., and J.M.D. contributed to the
experimental design. C.M. and G.G. performed computational analysis to
identify SIRT6mutations. S.K., J.L.F., J.M.D., and R.M. wrote the paper. All au-
thors discussed the results and commented on the manuscript.
ACKNOWLEDGMENTS
We thank members of the R.M. and J.M.D. labs for invaluable discussions and
advice. This work was supported in part by NIH grants 1R01CA175727-01A1,
DK088190-01A1 (to R.M.), and NIH GM065386 (to J.M.D). R.M. is the Kristine
and Bob Higgins MGH Research Scholar, the Warshaw Institute Fellow, and a
Howard Goodman Awardee. S.K. is the recipient of a Canadian Institutes of
Health Research postdoctoral fellowship. C.S. is supported by the Visionary
postdoctoral fellowship from the Department of Defense.
Received: May 19, 2015
Revised: July 30, 2015
Accepted: September 8, 2015
Published: October 8, 2015
REFERENCES
Albaugh, B.N., Arnold, K.M., Lee, S., and Denu, J.M. (2011). Autoacetylation of
the histone acetyltransferase Rtt109. J. Biol. Chem. 286, 24694–24701.
Avalos, J.L., Bever, K.M., and Wolberger, C. (2005). Mechanism of sirtuin inhi-
bition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2
enzyme. Mol. Cell 17, 855–868.ell Reports 13, 479–488, October 20, 2015 ª2015 The Authors 487
Du, J., Jiang, H., and Lin, H. (2009). Investigating the ADP-ribosyltransferase
activity of sirtuins with NAD analogues and 32P-NAD. Biochemistry 48,
2878–2890.
Feldman, J.L., Dittenhafer-Reed, K.E., and Denu, J.M. (2012). Sirtuin catalysis
and regulation. J. Biol. Chem. 287, 42419–42427.
Feldman, J.L., Baeza, J., and Denu, J.M. (2013). Activation of the protein de-
acetylase SIRT6 by long-chain fatty acids and widespread deacylation by
mammalian sirtuins. J. Biol. Chem. 288, 31350–31356.
Feldman, J.L., Dittenhafer-Reed, K.E., Kudo, N., Thelen, J.N., Ito, A., Yoshida,
M., and Denu, J.M. (2015). Kinetic and Structural Basis for Acyl-Group Selec-
tivity and NAD(+) Dependence in Sirtuin-Catalyzed Deacylation. Biochemistry
54, 3037–3050.
Gil, R., Barth, S., Kanfi, Y., and Cohen, H.Y. (2013). SIRT6 exhibits nucleo-
some-dependent deacetylase activity. Nucleic Acids Res. 41, 8537–8545.
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim,
R., Ge, E., Mostoslavsky, R., et al. (2013). SIRT6 regulates TNF-a secretion
through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110–113.
Kawahara, T.L., Michishita, E., Adler, A.S., Damian, M., Berber, E., Lin, M.,
McCord, R.A., Ongaigui, K.C., Boxer, L.D., Chang, H.Y., and Chua, K.F.
(2009). SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent
gene expression and organismal life span. Cell 136, 62–74.
Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A.,
Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., and Getz, G. (2014).
Discovery and saturation analysis of cancer genes across 21 tumour types.
Nature 505, 495–501.
Mao, Z., Hine, C., Tian, X., VanMeter, M., Au, M., Vaidya, A., Seluanov, A., and
Gorbunova, V. (2011). SIRT6 promotes DNA repair under stress by activating
PARP1. Science 332, 1443–1446.
Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., Damian,
M., Cheung, P., Kusumoto, R., Kawahara, T.L., Barrett, J.C., et al. (2008).
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chro-
matin. Nature 452, 492–496.488 Cell Reports 13, 479–488, October 20, 2015 ª2015 The AuthorsMostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gel-
lon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M.M., et al. (2006).
Genomic instability and aging-like phenotype in the absence of mammalian
SIRT6. Cell 124, 315–329.
Pan, P.W., Feldman, J.L., Devries, M.K., Dong, A., Edwards, A.M., and Denu,
J.M. (2011). Structure and biochemical functions of SIRT6. J. Biol. Chem. 286,
14575–14587.
Sebastia´n, C., Serra, M., Yeramian, A., Serrat, N., Lloberas, J., and Celada, A.
(2008). Deacetylase activity is required for STAT5-dependent GM-CSF
functional activity in macrophages and differentiation to dendritic cells.
J. Immunol. 180, 5898–5906.
Sebastia´n, C., Zwaans, B.M., Silberman, D.M., Gymrek, M., Goren, A., Zhong,
L., Ram, O., Truelove, J., Guimaraes, A.R., Toiber, D., et al. (2012). The histone
deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.
Cell 151, 1185–1199.
Tanner, K.G., Landry, J., Sternglanz, R., and Denu, J.M. (2000). Silent informa-
tion regulator 2 family of NAD- dependent histone/protein deacetylases gener-
ates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl. Acad. Sci. USA 97,
14178–14182.
Tennen, R.I., Berber, E., and Chua, K.F. (2010). Functional dissection of SIRT6:
identification of domains that regulate histone deacetylase activity and chro-
matin localization. Mech. Ageing Dev. 131, 185–192.
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr.,
and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–
1558.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309–314.
Zhong, L., D’Urso, A., Toiber, D., Sebastian, C., Henry, R.E., Vadysirisack,
D.D., Guimaraes, A., Marinelli, B., Wikstrom, J.D., Nir, T., et al. (2010). The his-
tone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140,
280–293.
